Latest Asx Listing News

Unith Ltd has responded to an ASX price query following unusual trading activity, denying undisclosed information and pointing to a successful recent roadshow as a potential factor.

Fintech Chain Limited has applied to delist from the ASX, citing low valuation, poor liquidity, and high costs, aiming to unlock growth capital in China and the US.

West Wits Mining Limited (WWI) has addressed recent spikes in its share price and trading volume, linking the activity to funding developments, a strong gold price, and positive market commentary.

Mayne Pharma has clarified why it did not disclose an FDA Untitled Letter to the market despite sharing it with its scheme bidder, reaffirming compliance with ASX rules amid recent share price volatility.

Infomedia Ltd has responded to an ASX price query following a sharp share price decline and increased trading volume, denying any undisclosed material information. The company pointed to the recent closure of Celeste Funds, a known shareholder, as a potential external factor influencing market activity.

Island Pharmaceuticals has raised $3.6 million through a strategic share placement to advance its lead antiviral drug ISLA-101’s clinical development and broaden its asset portfolio ahead of pivotal Phase 2a/b trial results.

Webjet Group Limited reports resilient FY25 results following its recent demerger, with a strategic plan to double transaction value by FY30. Despite macroeconomic headwinds, the company maintains strong cash reserves and outlines ambitious growth initiatives.

Janus Electric Holdings Limited will have its trading suspension lifted and resume quotation on the ASX from 21 May 2025 after meeting key listing requirements.

Macarthur Minerals has secured $250,000 through unsecured convertible notes to bolster its working capital and support ongoing operations amid challenging market conditions.

Yowie Group Ltd has firmly rejected the validity of director removal and nomination notices purportedly from Keybridge Capital, while confirming its status as Keybridge’s largest creditor with over $6.6 million owed. The company also detailed a recent share placement amid ongoing regulatory scrutiny.

Merino & Co has amended its quarterly report to correct expenditure figures and clarify related party payments, while reporting significant operational progress including new product launches and cryptocurrency integration.

Chimeric Therapeutics has raised $6.6 million through a discounted two-tranche placement to accelerate its promising CAR-T and NK cell therapy clinical programs. The capital raise, strongly backed by institutional and professional investors, signals growing confidence in the company’s oncology pipeline.